Navigation Links
Idera Pharmaceuticals Announces Presentations of Preclinical Data,on New Potential Oncology Applications of its TLR9 Agonists at AACR

the placebo group mean survival of 19.5 days).

Abstract 3548 entitled, "Antitumor activity of a synthetic agonist of TLR9 administered via intranasal route," was presented by Daqing Wang, Ph.D., of Idera Pharmaceuticals in the session Monoclonal Antibody Therapy and TLR Activation. In this study, the antitumor activity of a murine analog of IMO-2055 was examined following intranasal delivery in mouse models of colon carcinoma and melanoma metastasized to the lungs. Results show that the TLR9 agonist delivered by the intranasal route in the study lead to potent inhibition of lung metastases.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals is a drug discovery and development company that is developing drug candidates to treat cancer, infectious diseases, autoimmune diseases, allergy/asthma, and for use as vaccine adjuvants. Idera's proprietary drug candidates are designed to modulate TLRs, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. Idera's most advanced clinical candidate, IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial in oncology and in a Phase 1/2 chemotherapy combination trial in oncology. Idera has selected a second TLR9 agonist, IMO-2125, as a lead candidate for treating infectious diseases. Idera is collaborating with Novartis International Pharmaceutical, Ltd. for the discovery, development, and commercialization of TLR9 agonists for the treatment of asthma and allergy indications. Idera is also collaborating with Merck & Co., Inc. for the use of Idera's TLR7, 8 and 9 agonists in combination with Merck's therapeutic and prophylactic vaccines in the areas of oncology, infectious diseases, and Alzheimer's disease. For more information, visit www.iderapharma.com.

Forward Looking Statements

This press release contains forward-lookin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/4/2008)...the treatment of Acute Myeloid ...RNewswire/ -- Celator Pharmaceuticals today,announ... has granted orphan,drug designation to CPX-351 (C... treatment of Acute Myeloid Leukemia (AML)., Cela...ed Phase 2,studies with CPX-351. The first Phase 2...
(Date:9/4/2008)... -- Southern Research Institute,today announced th...ected,the organization to participate in the newly...r Network (MLPCN). The MLPCN -- a collaborative,re...es Program which is,designed to benefit human heal...me and validate future targets for drug discovery....
(Date:9/4/2008)...ion for Targeted Therapies That Ensur... BEACH, Calif., and AMSTERDAM, Netherlands, Sept. ...ular cancer diagnostics,today announced the launc...lows physicians to quantitatively determine the ge..., progesterone receptor (PR) and Human Epidermal,g...
(Date:9/3/2008)...earch and Education Foundation,s Within Our Reach..., Treating and Understanding R... time during its,unprecedented initiative to find ...ege of Rheumatology Research and Education Foundat...earch funded by the Within Our,Reach: Finding a Cu...
Breaking Medicine Technology:Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Agendia Launches TargetPrint(R) for Breast Cancer Patients 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Are blood thinners post op killers 3F 15527 1Are blood thinners post op killers 3F 15527 2Angina drug potentially useful against heart rhythm disorders 15525 1Angina drug potentially useful against heart rhythm disorders 15525 2Angina drug potentially useful against heart rhythm disorders 15525 3Specially designed soils could help combat climate change 2675 1Specially designed soils could help combat climate change 2675 2New National Public Health Program Shows Smokers How to Become an EX 15523 1New National Public Health Program Shows Smokers How to Become an EX 15523 2New National Public Health Program Shows Smokers How to Become an EX 15523 3New National Public Health Program Shows Smokers How to Become an EX 15523 4New National Public Health Program Shows Smokers How to Become an EX 15523 5
...nset and Total,Sleep Time, and key secondary endpo...met at both doses - Evotec to host a,conference ca...URG, Germany | OXFORD, England, June 4, 2007-- Evo...oday positive top-line,results from its first phas...ronic primary insomnia. EVT 201 is a partial,posit...
...nib - a selective,VEGF signaling inhibitor - shows... free at six months(1), CHICAGO, June 04, 2007 /PR...diranib (AZD2171) were presented today at,the annu...ology,(ASCO) from a study in patients with recurre...umor with a high unmet medical need.,(1) , Cediran...
Other Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4
(Date:9/7/2008)...Upon Students and University Leaders to, Join the ... to Big Tobacco, WASHINGTON, Sept. 8 /PRNewswire-... to aggressive tobacco industry marketing tactics ...ew report released today by the,American Lung Asso...rview of the current status of,tobacco use and pol...
(Date:9/5/2008)...e Latest Developments in Molecular,Testing and Per...Newswire-USNewswire/ -- The practice of,pathology ...d the promise,of personalized medicine will change...other imaging technologies will change the way pat...ts is taking a leadership role in,making sure that...
(Date:9/5/2008)...mane Shows Public Reluctant to Evacuate, Without T...fforts Confirm Survey ...urvey by the American Humane,Association found tha...stance if it meant leaving without their family pe... towards the U.S. coast, residents and,officials s...
(Date:9/5/2008)...to commit to develop a National AIDS,Strategy for ... /PRNewswire-USNewswire/ -- The,Republican Nationa...of the,domestic AIDS epidemic in the United States...as. Neither Presidential nominee Sen. John McCain ...tioned AIDS in their remarks,to Convention delegat...
Breaking Medicine News(10 mins):Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 2Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 3Health News:Big Tobacco's Grip on Colleges and Students Loosens, But Still Holding Strong: New Report Examines Trends on Campuses 4Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Nearly Half of Americans Won't Flee Without Fido 2Health News:Nearly Half of Americans Won't Flee Without Fido 3Health News:Nearly Half of Americans Won't Flee Without Fido 4Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...lished a definite link between risk of pelvic frac...o the study, women who receive radiotherapy for ce...isk// for fracture of the pelvis. This study highl...f cancer treatment in the elderly. Falls are the ...
...e over the safety of artificial sweeteners got an ...trol Council today stated that a rat study conduct...tradictory with the extensive scientific research ...The U.S. Food & Drug Administration (FDA) has said...
...tive groups in the United States, who had voiced v...ailability of the "morning-after" pill, are now ha...ical cancer vaccines.// These vaccines manufacture... still in the experimental stage and are years awa...
...e potential to be the healthcare crisis manager fo...ical tourism, experts say.// Speaking at a health ...dustry (CII) and the Indian Health Care Foundation...uld double the expenditure on healthcare and facil...
Other Medicine News:Health News:Radiation Risk of Pelvic Fracture in Elderly Women 2Health News:Aspartame, Artificial Sweetener, A Safe Bet! 2Health News:Aspartame, Artificial Sweetener, A Safe Bet! 3Health News:Religious groups overcome objections to cervical cancer vaccines 2Health News:India Can Manage World’s Healthcare Crisis By 202 2
The Diagnostic Automation, Inc. (DAI) Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection and semi-quantitative determination of IgG, A, M antibodies to MPO
Anti-RSV IgA Assay (ELISA).
Anti-RSV IgG Assay (ELISA).
Rapid Immunoassay for the detection of Respiratory Syncytial Virus.
Medicine Products: